ReviewCurrent treatment options in oncology2021
Surgical Management of Skull Base and Spine Chordomas.
Review in Current treatment options in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- The efficacy and safety of tyrosine kinase inhibitors in the treatment of advanced or metastatic chordoma: a single-arm meta-analysis.Neurosurgical review · 2025Pooled it
- Review
- Case Report: Anlotinib for advanced chordoma.Frontiers in oncology · 2026Article
- Impact of proton versus photon radiotherapy on overall survival in the management of spinal chordoma and mortality risk prediction: a nationwide analysis.Journal of neuro-oncology · 2025Article
- Real-time prognosis prediction with conditional survival analysis for skull base chordoma based on SEER.Translational cancer research · 2025Article
- Risk calculator for long-term survival prediction of spinal chordoma versus chondrosarcoma: a nationwide analysis.Journal of neuro-oncology · 2025Article
- Enhancing skull base tumor management: the combination of 3D printing technology and endoscopic surgical techniques.3D printing in medicine · 2025Article
- Individualized estimation of conditional survival for patients with spinal chordoma.Translational cancer research · 2025Article
- Case Report: Collision tumors of the sellar region: pituitary adenoma and chordoma coexist in the sellar region.Frontiers in endocrinology · 2025Article
- Immunologic and Targeted Molecular Therapies for Chordomas: A Narrative Review.Journal of clinical medicine · 2024Review
- Gross total resection and survival outcomes in elderly patients with spinal chordoma: a SEER-based analysis.Frontiers in oncology · 2023Article
- The critical roles of lnc-GLYATL2-2/PD-L1 axis in immune microenvironment and the clinical value of intracranial chordomas.American journal of cancer research · 2023Article
- Metastatic skull base chordoma: A systematic review.Laryngoscope investigative otolaryngology · 2022Review
- The impact of expanded endoscopic approaches on oncologic and functional outcomes for clival malignancies:a case series.Journal of neuro-oncology · 2022Article
- Surgical Effects of Resecting Skull Base Tumors Using Pre-operative Multimodal Image Fusion Technology: A Retrospective Study.Frontiers in neurology · 2022Article
- Fluorescent intraoperative navigation: trends and beyond.American journal of nuclear medicine and molecular imaging · 2022Article
- A chronicle review of new techniques that facilitate the understanding and development of optimal individualized therapeutic strategies for chordoma.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementManagement of chordoma along the cranial-spinal axis is a major challenge for both skull base and spinal surgeons. Although chordoma remains a rare tumor, occurring in approximately 1 per 1 million individuals, its treatment poses several challenges. These tumors are generally poorly responsive to radiation and chemotherapy, leading to surgical resection as the mainstay of treatment. Due to anatomic constraints and unique challenges associated with each primary site of disease, gross total resection is often not feasible and is associated with high rates of morbidity. Additionally, chordoma is associated with high rates of recurrence due to the tumor's aggressive biologic features, and postoperative radiation is increasingly incorporated as a treatment option for these patients. Despite these challenges, modern-day surgical techniques in both skull base and spinal surgery have facilitated improved patient outcomes. For example, endoscopic endonasal techniques have become the mainstay in resection of skull base chordomas, improving the ability to achieve gross total resection, while reducing associated morbidity of open transfacial techniques. Resection of spinal chordomas has been facilitated by emerging techniques in preoperative imaging, intraoperative navigation, spinal reconstruction, and radiotherapy. Taken collectively, the treatment of chordoma affecting the skull base and spinal requires a multidisciplinary team of surgeons, radiation oncologists, and medical oncologists who specialize in the treatment of this challenging disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.